Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
LENZ Therapeutics, Inc. (LENZ) had Return on Tangible Equity of -24.39% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-49.77M |
|
-- |
|
-- |
|
$58.61M |
|
$-58.61M |
|
$8.84M |
|
$-49.77M |
|
$-49.77M |
|
$-49.77M |
|
$-49.77M |
|
$-49.77M |
|
$-49.77M |
|
$-58.61M |
|
$-62.57M |
|
21.28M |
|
21.28M |
|
$-2.34 |
|
$-2.34 |
|
| Balance Sheet Financials | |
$211.92M |
|
$0.65M |
|
$3.39M |
|
$215.30M |
|
$10.41M |
|
-- |
|
$0.81M |
|
$11.22M |
|
$204.08M |
|
$204.08M |
|
$204.08M |
|
27.52M |
|
| Cash Flow Statement Financials | |
$-59.39M |
|
$-154.48M |
|
$199.00M |
|
$35.14M |
|
$20.27M |
|
$-14.87M |
|
$6.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-59.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.39% |
|
|
Return on Tangible Equity |
-24.39% |
-23.12% |
|
-24.39% |
|
$7.42 |
|
$-2.81 |
|
$-2.79 |
|